Slides From Hot Topics in NASH: Real-World Practice Implications of NASH Trial Designs

Expert faculty explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Kenneth Cusi, MD, FACP, FACE
Program Director
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.61 MB
Released: March 26, 2019

Acknowledgements

Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Unlocked slides from Brent Tetri, MD, and CCO: impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease

Brent A. Neuschwander-Tetri, MD Released: February 3, 2021

Expert commentary discussing the complex interplay among NASH, obesity, and diabetes from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 29, 2021 Expired: January 28, 2022

Stephen A. Harrison, MD, COL (Ret.), FAASLD, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Stephen A. Harrison, MD, COL (Ret.), FAASLD Released: March 29, 2019

Kenneth Cusi, MD, FACP, FACE, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Kenneth Cusi, MD, FACP, FACE
Program Director
Released: March 29, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue